NuGen Medical Devices has entered a five-year distribution agreement with Verrue Consulting Group for its needle-free InsuJet device in Belgium.

InsuJet is designed to enhance the administration of subcutaneous therapeutics for diabetics, aiming to improve care delivery and patient quality of life. It has received approval for sale in Belgium as a medical device.

Effective 17 December 2023, Verrue became an official distributor for the InsuJet device of NuGen.

NuGen expects the partnership to generate sales of $2.4m if the 7,300-device target is met during the agreement period.

The company anticipates a gross margin of 72% from this deal.

The distribution channels will include clinics, online platforms, pharmacies and local sales agents. InsuJet device sales training was completed last month by Verrue.

NuGen CCO Karen Dunlap said: “I am pleased to introduce Verrue who will be a distributor for the InsuJet needle-free injector in Belgium.

“Their experienced sales team will be introducing InsuJet’s advantages, features, and benefits for patients partnering with self-employed nurses/diabetes educators offering training and sales along with post-sales support.”

Verrue has identified a potential market of 770,000 patients with type 1 diabetes in Belgium, which will be the initial focus for InsuJet sales.

To support these efforts, Verrue plans to utilise a network of self-employed nurses and diabetes educators. This strategic partnership is expected to significantly impact the diabetic care landscape in Belgium.

Verrue general manager Johan Verrue said: “As a distributor for NuGen in Belgium, we are excited to revolutionise the Belgian diabetes market with InsuJet.

“We have started to make calls and schedule several appointments with our network of over 1,600+ independent nurses in Belgium alone. We are impressed with what we see and the changes we can deliver with the InsuJet to the diabetic market in Belgium.”